FDA review backs anti-clot drug from biotech goat's milk

01/7/2009 | USA Today

The FDA released a review of GTC Biotherapeutics' Atryn stating that the treatment proved safe and effective in preventing blood clots. The agency's Blood Products Advisory Board is scheduled Friday to discuss the report on the drug, which is derived from milk of biotech goats.

View Full Article in:

USA Today

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
Springfield, OR
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA